PARIS – Digital health company Voluntis has received clearance from the U.S. Food and Drug Administration, as well as CE mark, to integrate the basal insulin Toujeo into its Insulia digital companion for people with Type 2 diabetes. “We want to empower people with Type 2 diabetes to better manage their condition through technology,” said Pierre Leurent, CEO of Voluntis, in a statement. Insulia is a prescription-only digital companion for people with Type 2 diabetes and their care teams that helps people get to the right dose, every day. It combines a patient mobile app that provides real-time basal insulin dosage recommendations and educational coaching messages based on blood glucose values. A clinician web portal allows providers to configure personalized treatment plans and prescribe the app then follow their entire patient population remotely.
You are here: / / Voluntis gets green light to add Toujeo to Insulia diabetes management device